1. Pink Sheet
  2. >>Product Reviews
  3. >>Approvals

Adaptimmune Aims To Quickly Convert Teclera’s Accelerated Approval

 
• By Bridget Silverman

The first engineered cell therapy for a solid tumor could be submitted for full approval in synovial sarcoma next year.

building under construction
Adaptimmune plans to fill out its Teclera label with confirmatory evidence to be submitted 2025. • Source: Shutterstock

In contrast to the many cell and gene therapy accelerated approvals that have been criticized for lengthy confirmatory trial timelines, Adaptimmune Therapeutics plc is gearing up for a relatively quick bid for full approval of its newly cleared melanoma-associated antigen A4 (MAGE-A4)-directed autologous T-cell immunotherapy Teclera (afamitresgene autoleucel).

Key Takeaways

  • Adaptimmune’s MAGE-A4 directed autologous T-cell therapy Teclera earned accelerated approval 1 August for chemotherapy-experienced synovial sarcoma patients who have specific HLA types and whose tumors express the MAGE-A4 antigen.

Confirmatory evidence is expected to be submitted to the FDA “next year to complete that obligation and convert this application...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approvals

EU Decision Time For Madrigal’s MASH Drug Resmetirom And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ resmetirom could become the first approved treatment for non-cirrhotic metabolic dysfunction-associated steatohepatitis in the EU, if the European Medicines Agency issues a positive opinion for the drug later this week.

Blenrep’s Comeback Continues As England Becomes First To Fund Drug

 
• By Eliza Slawther

Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.

Argentina Speeds Up Market Access Process

 
• By Francesca Bruce

Companies operating in Argentina may get their medicines to the market more quickly thanks to new updates to the medicines authorization system.

US FDA’s June Approval Forecast: Infection Prevention, Cancer And HAE

 
• By Bridget Silverman

Upcoming FDA user fee goal dates include novel products from a busy lung cancer pipeline, a single-dose passive immunization against RSV for infants, what could be the first oral HAE acute treatment, and a first-in-class HAE preventive antibody.

More from Product Reviews

US FDA’s July AdComms: Pediatric Vaccine Safety, Blenrep’s Return, (Maybe) Capricor’s Cell Therapy

 
• By Sue Sutter

The Pediatric Advisory Committee will review postmarketing safety for three vaccines and the oncologic drugs panel will consider the return of GSK’s belantamab mafodotin. An FDA notice about a 30 July meeting on Capricor’s deramiocel for Duchenne muscular dystrophy was withdrawn.

Recent And Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

Blenrep’s Comeback Continues As England Becomes First To Fund Drug

 
• By Eliza Slawther

Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.